CompletedNot Applicable

Integrating Pharmacogenetics In Clinical Care

United States408 participantsStarted 2016-08-01

Plain-language summary

This study will determine whether using a genetic test (for the SLCO1B1 gene) can help patients and providers choose the right type and dose of cholesterol-lowering statin medications to lower the risk of cardiovascular disease, while minimizing the muscle pain side effects that sometimes occur with statins.

Who can participate

Age range40 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Providers: * All providers in Primary Care and Women's Health at VA Boston Healthcare System will be eligible to participate. Patients: * Aged 40-75 years * Have no history of statin use * Have received VA care for at least the prior 6 months * Are a patient of an enrolled provider * Meet at least 1 of the following criteria: * cardiovascular disease (CVD) * diabetes * LDL cholesterol value \>= 190 mg/dL * 10-year CVD risk of 7.5%, calculated with the ACC/AHA 2013 pooled risk equations Exclusion Criteria: * Patients will be ineligible if they: * Do not meet the inclusion criteria * Pregnant * Incarcerated or institutionalized

What they're measuring

12-Month Change in LDL Cholesterol

Timeframe: 12 months

Trial details

NCT IDNCT02871934

SponsorVA Office of Research and Development

Sponsor typeFED

Study typeINTERVENTIONAL

Primary completion2020-12-31

Results submitted2021-11-22

View on ClinicalTrials.gov More Cardiovascular Disease trials